Synaptogenix (NASDAQ:SNPX) Posts Quarterly Earnings Results, Misses Estimates By $2.30 EPS

Synaptogenix (NASDAQ:SNPX) posted its quarterly earnings data on Thursday. The company reported ($4.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.06) by ($2.30), Zacks reports.

Synaptogenix Trading Up 0.4 %

Shares of SNPX stock opened at $2.68 on Friday. The firm’s fifty day moving average price is $2.95 and its two-hundred day moving average price is $3.02. Synaptogenix has a 1 year low of $2.15 and a 1 year high of $6.22.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.